Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: Business Wire
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2, placebo-controlled, clinical trial of AG013 in oral mucositis presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.Titled, “Severe oral mucositis (SOM) mitigation by genetically modified Lactococcus lactis bacteria (LLB) producing human trefoil factor 1 (hTFF1; AG013) in patients being treated with concomitant chemoradiation (CRT) for oral and oropharyngeal cancers (OCOPC),” was presented at the ESMO Congress 2019 in Barcelona, Spain. The poster can be found under the “Presentations” tab in the “News and Media” section of the Company's website, located at www.oragenics.com.The poster presentation describes the methods and initial blinded results from the ongoing Ph
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards [Yahoo! Finance]Yahoo! Finance
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsBusiness Wire
- Oragenics, Inc. (NYSE: OGEN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
OGEN
Sec Filings
- 4/22/24 - Form 8-K
- 4/16/24 - Form 8-K
- 3/29/24 - Form 10-K
- OGEN's page on the SEC website